Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
vlag T2 Biosystems Inc 3/07 0,002 USD
0,00% 		0,00%
vlag Taysha Gene Therapies Inc 2/07 6,530 USD
-1,80% 		-1,80%
vlag TG Therapeutics Inc 2/07 53,310 USD
-0,39% 		-0,39%
vlag Tilray, Inc. 2/07 4,620 USD
+4,29% 		+4,29%
vlag Tiziana Life Sciences Plc 2/07 1,310 USD
+6,50% 		+6,50%
vlag TME Pharma N.V. 3/07 0,074 EUR
-1,21% 		-1,21%
vlag Transgene S.A. 3/07 0,755 EUR
+3,85% 		+3,85%
vlag Travere Therapeutics Inc 2/07 56,920 USD
+1,03% 		+1,03%
vlag Trevena Inc 2/07 0,002 USD
0,00% 		0,00%
vlag Twist Bioscience Corp 2/07 99,240 USD
-2,94% 		-2,94%

Nieuws over “Biotechnologie”

4/07 · ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

4/07 · ADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline · Persbericht

2/07 · Monthly information on share capital and company voting rights · Persbericht

2/07 · Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026 · Persbericht

2/07 · GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH · Persbericht

2/07 · Declaration voting rights - June 30,2026 · Persbericht

2/07 · ADMA SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ADMA Biologics Investors of Securities Class Action Lawsuit Deadline on August 10, 2026 · Persbericht

1/07 · Neurocrine Biosciences Initiates Phase 2 Study of Crinecerfont in Pediatric Patients Under 4 Years Old with Classic Congenital Adrenal Hyperplasia · Persbericht

1/07 · Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1/07 · ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit · Persbericht

1/07 · ADMA DEADLINE: Levi & Korsinsky Reminds ADMA BIOLOGICS, INC. Investors of Upcoming Securities Class Action Deadline · Persbericht

1/07 · Co-Diagnostics Completes Clinical and Analytical Studies in Preparation for FDA 510(k) Submission of Upper Respiratory Point-of-Care Test · Persbericht

1/07 · Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer · Persbericht

1/07 · ADMA Biologics, Inc. (NASDAQ: ADMA) Investors Have Opportunity to Lead Securities Fraud Class Action Lawsuit · Persbericht

30/06 · Halozyme Appoints David Ramsay as President Drug Delivery · Persbericht

30/06 · Acquisition of Own Shares · Persbericht

30/06 · Inkoop van eigen aandelen · Persbericht

30/06 · A Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting Drugs · Persbericht

30/06 · COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.6 MILLION PRIVATE PLACEMENT · Persbericht

30/06 · $ADMA Notification: ADMA Biologics Accused of Misrepresentations about its Revenue Sources in Securities Fraud Class Action · Persbericht

30/06 · Just - Evotec Biologics Launches J.TRAIN to Deliver Turnkey Continuous Manufacturing for Biologics · Persbericht

Mijn selecties